{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T03:10:07Z","timestamp":1783825807314,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UM1 CA186689"],"award-info":[{"award-number":["UM1 CA186689"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA068485"],"award-info":[{"award-number":["P30 CA068485"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,4,15]]},"DOI":"10.1007\/s10637-018-0663-0","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T05:46:49Z","timestamp":1536212809000},"page":"315-322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer"],"prefix":"10.1007","volume":"37","author":[{"given":"Laura W.","family":"Goff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilofer S.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer G.","family":"Whisenant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulka","family":"Vaishampayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Hochster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Weise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia M.","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safia N.","family":"Salaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"El-Rifai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan D.","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"issue":"8","key":"663_CR1","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1634\/theoncologist.2009-0019","volume":"14","author":"DS Boss","year":"2009","unstructured":"Boss DS, Beijnen JH, Schellens JH (2009) Clinical experience with aurora kinase inhibitors: a review. Oncologist 14(8):780\u2013793. https:\/\/doi.org\/10.1634\/theoncologist.2009-0019","journal-title":"Oncologist"},{"issue":"Pt 21","key":"663_CR2","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1242\/jcs.112.21.3591","volume":"112","author":"R Giet","year":"1999","unstructured":"Giet R, Prigent C (1999) Aurora\/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases. J Cell Sci 112(Pt 21):3591\u20133601","journal-title":"J Cell Sci"},{"issue":"3","key":"663_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biolcel.2003.09.008","volume":"96","author":"R Crane","year":"2004","unstructured":"Crane R, Gadea B, Littlepage L, Wu H, Ruderman JV (2004) Aurora A, meiosis and mitosis. Biol Cell 96(3):215\u2013229. https:\/\/doi.org\/10.1016\/j.biolcel.2003.09.008","journal-title":"Biol Cell"},{"issue":"7","key":"663_CR4","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1083\/jcb.200108051","volume":"155","author":"E Hannak","year":"2001","unstructured":"Hannak E, Kirkham M, Hyman AA, Oegema K (2001) Aurora-a kinase is required for centrosome maturation in Caenorhabditis elegans. J Cell Biol 155(7):1109\u20131116. https:\/\/doi.org\/10.1083\/jcb.200108051","journal-title":"J Cell Biol"},{"issue":"12","key":"663_CR5","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1128\/MCB.02364-06","volume":"27","author":"K Hoar","year":"2007","unstructured":"Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Roy N, Ecsedy JA (2007) MLN8054, a small-molecule inhibitor of aurora a, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 27(12):4513\u20134525. https:\/\/doi.org\/10.1128\/MCB.02364-06","journal-title":"Mol Cell Biol"},{"issue":"51","key":"663_CR6","doi-asserted-by":"publisher","first-page":"51786","DOI":"10.1074\/jbc.M306275200","volume":"278","author":"T Marumoto","year":"2003","unstructured":"Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E, Saya H (2003) Aurora-a kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 278(51):51786\u201351795. https:\/\/doi.org\/10.1074\/jbc.M306275200","journal-title":"J Biol Chem"},{"issue":"1","key":"663_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0092-8674(95)90374-7","volume":"81","author":"DM Glover","year":"1995","unstructured":"Glover DM, Leibowitz MH, McLean DA, Parry H (1995) Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 81(1):95\u2013105","journal-title":"Cell"},{"issue":"49","key":"663_CR8","doi-asserted-by":"publisher","first-page":"46219","DOI":"10.1074\/jbc.M107540200","volume":"276","author":"H Katayama","year":"2001","unstructured":"Katayama H, Zhou H, Li Q, Tatsuka M, Sen S (2001) Interaction and feedback regulation between STK15\/BTAK\/aurora-a kinase and protein phosphatase 1 through mitotic cell division cycle. J Biol Chem 276(49):46219\u201346224. https:\/\/doi.org\/10.1074\/jbc.M107540200","journal-title":"J Biol Chem"},{"issue":"5","key":"663_CR9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S0092-8674(03)00642-1","volume":"114","author":"T Hirota","year":"2003","unstructured":"Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, Hatakeyama K, Saya H (2003) Aurora-a and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 114(5):585\u2013598","journal-title":"Cell"},{"issue":"4","key":"663_CR10","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1128\/MCB.01062-08","volume":"29","author":"DO Cowley","year":"2009","unstructured":"Cowley DO, Rivera-Perez JA, Schliekelman M, He YJ, Oliver TG, Lu L, O'Quinn R, Salmon ED, Magnuson T, Van Dyke T (2009) Aurora-a kinase is essential for bipolar spindle formation and early development. Mol Cell Biol 29(4):1059\u20131071. https:\/\/doi.org\/10.1128\/MCB.01062-08","journal-title":"Mol Cell Biol"},{"issue":"46","key":"663_CR11","doi-asserted-by":"publisher","first-page":"31785","DOI":"10.1074\/jbc.M805880200","volume":"283","author":"LY Lu","year":"2008","unstructured":"Lu LY, Wood JL, Ye L, Minter-Dykhouse K, Saunders TL, Yu X, Chen J (2008) Aurora a is essential for early embryonic development and tumor suppression. J Biol Chem 283(46):31785\u201331790. https:\/\/doi.org\/10.1074\/jbc.M805880200","journal-title":"J Biol Chem"},{"issue":"1","key":"663_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ydbio.2012.08.010","volume":"371","author":"Y Yoon","year":"2012","unstructured":"Yoon Y, Cowley DO, Gallant J, Jones SN, Van Dyke T, Rivera-Perez JA (2012) Conditional aurora a deficiency differentially affects early mouse embryo patterning. Dev Biol 371(1):77\u201385. https:\/\/doi.org\/10.1016\/j.ydbio.2012.08.010","journal-title":"Dev Biol"},{"issue":"1","key":"663_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ccr.2008.12.005","volume":"15","author":"T Otto","year":"2009","unstructured":"Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R, Christiansen H, Berwanger B, Eilers M (2009) Stabilization of N-Myc is a critical function of aurora a in human neuroblastoma. Cancer Cell 15(1):67\u201378. https:\/\/doi.org\/10.1016\/j.ccr.2008.12.005","journal-title":"Cancer Cell"},{"issue":"6","key":"663_CR14","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/onc.2008.434","volume":"28","author":"AA Dar","year":"2009","unstructured":"Dar AA, Belkhiri A, El-Rifai W (2009) The aurora kinase a regulates GSK-3beta in gastric cancer cells. Oncogene 28(6):866\u2013875. https:\/\/doi.org\/10.1038\/onc.2008.434","journal-title":"Oncogene"},{"issue":"11","key":"663_CR15","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1093\/emboj\/17.11.3052","volume":"17","author":"JR Bischoff","year":"1998","unstructured":"Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ, Plowman GD (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17(11):3052\u20133065. https:\/\/doi.org\/10.1093\/emboj\/17.11.3052","journal-title":"EMBO J"},{"issue":"54","key":"663_CR16","doi-asserted-by":"publisher","first-page":"7148","DOI":"10.1038\/sj.onc.1209707","volume":"25","author":"X Wang","year":"2006","unstructured":"Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T, Deng CX (2006) Overexpression of aurora kinase a in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 25(54):7148\u20137158. https:\/\/doi.org\/10.1038\/sj.onc.1209707","journal-title":"Oncogene"},{"issue":"2","key":"663_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/2496","volume":"20","author":"H Zhou","year":"1998","unstructured":"Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S (1998) Tumour amplified kinase STK15\/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20(2):189\u2013193. https:\/\/doi.org\/10.1038\/2496","journal-title":"Nat Genet"},{"issue":"4","key":"663_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.4161\/cbt.6.4.3817","volume":"6","author":"N Nishida","year":"2007","unstructured":"Nishida N, Nagasaka T, Kashiwagi K, Boland CR, Goel A (2007) High copy amplification of the aurora-a gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther 6(4):525\u2013533","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"663_CR19","first-page":"991","volume":"9","author":"D Li","year":"2003","unstructured":"Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, Friess H, Sen S (2003) Overexpression of oncogenic STK15\/BTAK\/aurora a kinase in human pancreatic cancer. Clin Cancer Res 9(3):991\u2013997","journal-title":"Clin Cancer Res"},{"issue":"3","key":"663_CR20","first-page":"593","volume":"12","author":"K Kamada","year":"2004","unstructured":"Kamada K, Yamada Y, Hirao T, Fujimoto H, Takahama Y, Ueno M, Takayama T, Naito A, Hirao S, Nakajima Y (2004) Amplification\/overexpression of aurora-a in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis. Oncol Rep 12(3):593\u2013599","journal-title":"Oncol Rep"},{"issue":"5","key":"663_CR21","first-page":"1083","volume":"17","author":"SB Yang","year":"2007","unstructured":"Yang SB, Zhou XB, Zhu HX, Quan LP, Bai JF, He J, Gao YN, Cheng SJ, Xu NZ (2007) Amplification and overexpression of aurora-a in esophageal squamous cell carcinoma. Oncol Rep 17(5):1083\u20131088","journal-title":"Oncol Rep"},{"issue":"4","key":"663_CR22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1158\/1535-7163.451.3.4","volume":"3","author":"S Rojanala","year":"2004","unstructured":"Rojanala S, Han H, Munoz RM, Browne W, Nagle R, Von Hoff DD, Bearss DJ (2004) The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther 3(4):451\u2013457","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"663_CR23","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-1057-03","volume":"10","author":"YM Jeng","year":"2004","unstructured":"Jeng YM, Peng SY, Lin CY, Hsu HC (2004) Overexpression and amplification of aurora-a in hepatocellular carcinoma. Clin Cancer Res 10(6):2065\u20132071","journal-title":"Clin Cancer Res"},{"issue":"8","key":"663_CR24","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/cncr.23371","volume":"112","author":"AA Dar","year":"2008","unstructured":"Dar AA, Zaika A, Piazuelo MB, Correa P, Koyama T, Belkhiri A, Washington K, Castells A, Pera M, El-Rifai W (2008) Frequent overexpression of aurora kinase a in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 112(8):1688\u20131698. https:\/\/doi.org\/10.1002\/cncr.23371","journal-title":"Cancer"},{"issue":"5","key":"663_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1593\/neo.09154","volume":"11","author":"Y Baba","year":"2009","unstructured":"Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, Kirkner GJ, Goel A, Fuchs CS, Ogino S (2009) Aurora-a expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia 11(5):418\u2013425","journal-title":"Neoplasia"},{"issue":"11","key":"663_CR26","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1158\/0008-5472.CAN-09-3953","volume":"70","author":"P Cammareri","year":"2010","unstructured":"Cammareri P, Scopelliti A, Todaro M, Eterno V, Francescangeli F, Moyer MP, Agrusa A, Dieli F, Zeuner A, Stassi G (2010) Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res 70(11):4655\u20134665. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3953","journal-title":"Cancer Res"},{"issue":"24","key":"663_CR27","doi-asserted-by":"publisher","first-page":"7614","DOI":"10.1158\/1078-0432.CCR-11-1536","volume":"17","author":"MG Manfredi","year":"2011","unstructured":"Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ, Wysong DR, Janowick DA, Hyer ML, Leroy PJ, Gershman RE, Silva MD, Germanos MS, Bolen JB, Claiborne CF, Sells TB (2011) Characterization of alisertib (MLN8237), an investigational small-molecule inhibitor of aurora a kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 17(24):7614\u20137624. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1536","journal-title":"Clin Cancer Res"},{"key":"663_CR28","doi-asserted-by":"crossref","first-page":"A1592","DOI":"10.1182\/blood.V112.11.1592.1592","volume":"112","author":"JJ Huck","year":"2008","unstructured":"Huck JJ, Zhang M, Hyer ML, Manfredi MG (2008) Anti-tumor activity of the aurora a inhibitor MLN8237 in diffuse large B-cell lymphoma preclinical models. Blood 112:A1592","journal-title":"Blood"},{"issue":"1","key":"663_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/1078-0432.CCR-13-1187","volume":"20","author":"V Sehdev","year":"2014","unstructured":"Sehdev V, Katsha A, Arras J, Peng D, Soutto M, Ecsedy J, Zaika A, Belkhiri A, El-Rifai W (2014) HDM2 regulation by AURKA promotes cell survival in gastric cancer. Clin Cancer Res 20(1):76\u201386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1187","journal-title":"Clin Cancer Res"},{"issue":"6","key":"663_CR30","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1053\/j.gastro.2013.08.050","volume":"145","author":"A Katsha","year":"2013","unstructured":"Katsha A, Soutto M, Sehdev V, Peng D, Washington MK, Piazuelo MB, Tantawy MN, Manning HC, Lu P, Shyr Y, Ecsedy J, Belkhiri A, El-Rifai W (2013) Aurora kinase a promotes inflammation and tumorigenesis in mice and human gastric neoplasia. Gastroenterology 145(6):1312\u20131322 e1\u20138. https:\/\/doi.org\/10.1053\/j.gastro.2013.08.050","journal-title":"Gastroenterology"},{"issue":"21","key":"663_CR31","doi-asserted-by":"publisher","first-page":"8998","DOI":"10.1158\/0008-5472.CAN-08-2658","volume":"68","author":"AA Dar","year":"2008","unstructured":"Dar AA, Belkhiri A, Ecsedy J, Zaika A, El-Rifai W (2008) Aurora kinase a inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res 68(21):8998\u20139004. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2658","journal-title":"Cancer Res"},{"issue":"7","key":"663_CR32","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.bcp.2011.01.017","volume":"81","author":"W Qi","year":"2011","unstructured":"Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Manziolli A, Persky DO, Miller TP, Mahadevan D (2011) Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol 81(7):881\u2013890. https:\/\/doi.org\/10.1016\/j.bcp.2011.01.017","journal-title":"Biochem Pharmacol"},{"issue":"15_suppl","key":"663_CR33","doi-asserted-by":"publisher","first-page":"8553","DOI":"10.1200\/jco.2009.27.15_suppl.8553","volume":"27","author":"M Zhang","year":"2009","unstructured":"Zhang M, Huck J, Hyer M, Ecsedy J, Manfredi M (2009) Effect of aurora a kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. J Clin Oncol 27(15_suppl):8553\u20138553. https:\/\/doi.org\/10.1200\/jco.2009.27.15_suppl.8553","journal-title":"J Clin Oncol"},{"issue":"3","key":"663_CR34","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1158\/1535-7163.MCT-11-0623","volume":"11","author":"V Sehdev","year":"2012","unstructured":"Sehdev V, Peng D, Soutto M, Washington MK, Revetta F, Ecsedy J, Zaika A, Rau TT, Schneider-Stock R, Belkhiri A, El-Rifai W (2012) The aurora kinase a inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther 11(3):763\u2013774. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0623","journal-title":"Mol Cancer Ther"},{"issue":"suppl 4; abstr","key":"663_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1200\/jco.2012.30.4_suppl.58","volume":"30","author":"V Sehdev","year":"2012","unstructured":"Sehdev V, Soutto M, Belkhiri A, Ecsedy J, El-Rifai W (2012) Effect of a combination of aurora kinase a inhibitor MLN-8237 and cisplatin on gastrointestinal tumors. J Clin Oncol 30(suppl 4; abstr 58):58","journal-title":"J Clin Oncol"},{"issue":"34","key":"663_CR36","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1200\/JCO.2009.23.4344","volume":"27","author":"B Chibaudel","year":"2009","unstructured":"Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, Dupuis O, Colin P, Larsen AK, Afchain P, Tournigand C, Louvet C, de Gramont A (2009) Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol 27(34):5727\u20135733. https:\/\/doi.org\/10.1200\/JCO.2009.23.4344","journal-title":"J Clin Oncol"},{"issue":"1","key":"663_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21387","journal-title":"CA Cancer J Clin"},{"key":"663_CR38","unstructured":"American Cancer Society. Cancer Facts & Figures 2017. (2017). Atlanta: American Cancer Society"},{"issue":"4","key":"663_CR39","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1470-2045(15)70051-3","volume":"16","author":"B Melichar","year":"2015","unstructured":"Melichar B, Adenis A, Lockhart AC, Bennouna J, Dees EC, Kayaleh O, Obermannova R, DeMichele A, Zatloukal P, Zhang B, Ullmann CD, Schusterbauer C (2015) Safety and activity of alisertib, an investigational aurora kinase a inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol 16(4):395\u2013405. https:\/\/doi.org\/10.1016\/S1470-2045(15)70051-3","journal-title":"Lancet Oncol"},{"issue":"1","key":"663_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ygyno.2012.06.040","volume":"127","author":"UA Matulonis","year":"2012","unstructured":"Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, Kutarska E, Liu H, Fingert H, Zhou X, Danaee H, Schilder RJ (2012) Phase II study of MLN8237 (alisertib), an investigational aurora a kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol 127(1):63\u201369. https:\/\/doi.org\/10.1016\/j.ygyno.2012.06.040","journal-title":"Gynecol Oncol"},{"issue":"17","key":"663_CR41","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1158\/1078-0432.CCR-12-0571","volume":"18","author":"A Cervantes","year":"2012","unstructured":"Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Rosello S, Andreu J, Jung J, Sanchis-Garcia JM, Piera A, Blasco I, Manos L, Perez-Fidalgo JA, Fingert H, Baselga J, Tabernero J (2012) Phase I pharmacokinetic\/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18(17):4764\u20134774. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0571","journal-title":"Clin Cancer Res"},{"issue":"16","key":"663_CR42","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1002\/cncr.30073","volume":"122","author":"JN Graff","year":"2016","unstructured":"Graff JN, Higano CS, Hahn NM, Taylor MH, Zhang B, Zhou X, Venkatakrishnan K, Leonard EJ, Sarantopoulos J (2016) Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora a kinase inhibitor, with docetaxel in patients with solid tumors. Cancer 122(16):2524\u20132533. https:\/\/doi.org\/10.1002\/cncr.30073","journal-title":"Cancer"},{"issue":"12","key":"663_CR43","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1200\/JCO.2015.65.4889","volume":"34","author":"SG DuBois","year":"2016","unstructured":"DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP (2016) Phase I study of the aurora a kinase inhibitor alisertib in combination with irinotecan and Temozolomide for patients with relapsed or refractory neuroblastoma: a NANT (new approaches to neuroblastoma therapy) trial. J Clin Oncol 34(12):1368\u20131375. https:\/\/doi.org\/10.1200\/JCO.2015.65.4889","journal-title":"J Clin Oncol"},{"issue":"10","key":"663_CR44","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1111\/j.1582-4934.2010.01218.x","volume":"15","author":"KR Kelly","year":"2011","unstructured":"Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS (2011) The novel aurora a kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med 15(10):2057\u20132070. https:\/\/doi.org\/10.1111\/j.1582-4934.2010.01218.x","journal-title":"J Cell Mol Med"},{"issue":"10","key":"663_CR45","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1073\/pnas.0608798104","volume":"104","author":"MG Manfredi","year":"2007","unstructured":"Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ, Ray ET, Sells TB, Stringer B, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Bolen JB, Claiborne CF (2007) Antitumor activity of MLN8054, an orally active small-molecule inhibitor of aurora a kinase. Proc Natl Acad Sci U S A 104(10):4106\u20134111. https:\/\/doi.org\/10.1073\/pnas.0608798104","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"31","key":"663_CR46","doi-asserted-by":"publisher","first-page":"50290","DOI":"10.18632\/oncotarget.10366","volume":"7","author":"TM Pitts","year":"2016","unstructured":"Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, Messersmith WA, Ecsedy JA, Eckhardt SG (2016) Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. Oncotarget 7(31):50290\u201350301. https:\/\/doi.org\/10.18632\/oncotarget.10366","journal-title":"Oncotarget"}],"updated-by":[{"DOI":"10.1007\/s10637-018-0679-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T00:00:00Z","timestamp":1539820800000}}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0663-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0663-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0663-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:30:47Z","timestamp":1678559447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0663-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,6]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4,15]]}},"alternative-id":["663"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0663-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10637-018-0679-5","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,6]]},"assertion":[{"value":"22 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LWG has served as a consultant for Celgene and has institutional research funding from Astellas Pharma, Pfizer, Onxy, SunPharma, Lilly, and Bristol-Myers Squibb. SS has participated in advisory boards for Genentech Roche and Merck. HH has served as a consultant for Bayer, Genentech, and Merck. RC has received research grants from Macrogenics, Novartis, Puma Biotechnology, Merck, Merrimack, and Genentech. JB has served as a consultant for Celgene, Genentech, Aduro, Boston Biomedical, Janssen, Cornerstone, Symphogen, and Bayer and has institutional research funding from Genentech, Abbvie, Taiho, Bayer, 5Prime, Phoenix, Incyte, and Vertex. For the remaining authors, none were declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained for all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}